Comparative assessment and monitoring of deterioration of articulatory organs using subjective and objective tools among patients with amyotrophic lateral sclerosis

Wioletta Pawlukowska, Bartłomiej Baumert, Monika Gołąb-Janowska, Agnieszka Meller, Karolina Machowska-Sempruch, Agnieszka Wełnicka, Edyta Paczkowska, Iwona Rotter, Bogusław Machaliński, Przemysław Nowacki, Wioletta Pawlukowska, Bartłomiej Baumert, Monika Gołąb-Janowska, Agnieszka Meller, Karolina Machowska-Sempruch, Agnieszka Wełnicka, Edyta Paczkowska, Iwona Rotter, Bogusław Machaliński, Przemysław Nowacki

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease of a rapid course. In 25% of ALS sufferers, speech disorders occur as prodromal symptoms of the disease. Impaired communication affects physical health and has a negative impact on mental and emotional condition. In this study, we assessed which domains of speech are particularly affected in ALS. Subsequently, we estimated possible correlations between the ALS patients' subjective perception of their speech quality and an objective assessment of the speech organs carried out by an expert.

Methods: The study group consisted of 63 patients with sporadic ALS. The patients were examined for articulatory functions by means of Voice Handicap Index (VHI) and the Frenchay Dysarthria Assessment (FDA).

Results: On the basis of the VHI scores, the entire cohort was divided into 2 groups: group I (40 subjects) with mild speech impairment, and group II (23 subjects) displaying moderate and profound speech deficits. In an early phase of ALS, changes were typically reported in the tongue, lips and soft palate. The FDA and VHI-based measurements revealed a high, positive correlation between the objective and subjective evaluation of articulation quality.

Conclusions: Deterioration of the articulatory organs resulted in the reduction of social, physical and emotional functioning. The highly positive correlation between the VHI and FDA scales seems to indicate that the VHI questionnaire may be a reliable, self-contained tool for monitoring the course and progression of speech disorders in ALS.

Trial registration: NCT02193893 .

Keywords: Amyotrophic lateral sclerosis; Dysarthria; Frenchay Dysarthria Assessment; Speech disorders; Voice Handicap Index.

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Goodall EF, Morrison KE. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment. Expert Rev Mol Med. 2006;8:1–22. doi: 10.1017/S1462399406010854.
    1. Tavares de Andrade HM, Cintra VP, de Albuquerque M, Piccinin CC, Bonadia LC, Duarte Couteiro RE, et al. Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients. Neurobiol Aging. 2018;69:292.e15–292.e18. doi: 10.1016/j.neurobiolaging.2018.04.020.
    1. Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;13(377):162–172. doi: 10.1056/NEJMra1603471.
    1. Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;4(390):2084–2098.
    1. Duffy J. Unilateral upper motor neuron dysarthria. In: Motor speech disorders: substrates, differential diagnosis, and management, 3rd: Mosby; Elsevier Health Sciences; 2012. p. 255–73.
    1. Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: a review. Amyotroph Lateral Scler. 2010;11:4–15. doi: 10.3109/17482960802379004.
    1. Körner S, Sieniawski M, Kollewe K, Rath KJ, Krampfl K, Zapf A, et al. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:20–25. doi: 10.3109/17482968.2012.692382.
    1. Watts CR, Vanryckeghem M. Laryngeal dysfunction in amyotrophic lateral sclerosis: a review and case report. BMC Ear Nose Throat Disord. 2001;1:1. doi: 10.1186/1472-6815-1-1.
    1. Mefferd AS, Green JR, Pattee G. A novel fixed-target task to determine articulatory speed constraints in persons with amyotrophic lateral sclerosis. J Commun Disord. 2012;45:35–45. doi: 10.1016/j.jcomdis.2011.09.002.
    1. Mefferd AS, Pattee GL, Green JR. Speaking rate effects on articulatory pattern consistency in talkers with mild ALS. Clin Linguist Phon. 2014;28:799–811. doi: 10.3109/02699206.2014.908239.
    1. Yunusova Y, Weismer GG, Lindstrom MJ. Classifications of vocalic segments from articulatory kinematics: healthy controls and speakers with dysarthria. J Speech Lang Hear Res. 2011;54:1302–1311. doi: 10.1044/1092-4388(2011/09-0193).
    1. Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: a speech subsystem approach. Behav Neurol. 2015;2015:183027. doi: 10.1155/2015/183027.
    1. Rong P, Yunusova Y, Wang J, Zinman L, Pattee LG, Berry JD, et al. Predicting speech intelligibility decline in amyotrophic lateral sclerosis based on the deterioration of individual speech subsystems. PLoS One. 2016;11:e0154971. doi: 10.1371/journal.pone.0154971.
    1. Couratier P, Torny F, Lacoste M. Functional rating scales for amyotrophic lateral sclerosis. Rev Neurol (Paris) 2006;162:502–507. doi: 10.1016/S0035-3787(06)75041-X.
    1. Enderby P, Palmer R. FDA-2. The Frenchay Dysarthria Assessment. Examiner’s Manual. 2. Austin: Pro-Ed; 2008.
    1. Yorkston K, Beukelman DR, Hakel M, Dorsey M. Sentence intelligibility test for windows. Lincoln: Institute for Rehabilitation Science and Engineering at Madonna Rehabilitation Hospital; 2007.
    1. Ball L, Beukelman D, Ullman C, Maassen K, Pattee G. Monitoring speaking rate by telephone for persons with amyotrophic lateral sclerosis. J Med Speech Lan Path. 2005;13:233–240.
    1. Kent RD, Vorperian HK, Kent JF, Duffy JR. Voice dysfunction in dysarthria: application of the multi-dimensional voice program. J Commun Disord. 2003;36:281–306. doi: 10.1016/S0021-9924(03)00016-9.
    1. Jacobson BH, Jonson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech Lang Pathol. 1997;6:66–70. doi: 10.1044/1058-0360.0603.66.
    1. Sobuś A, Baumert B, Litwińska Z, Gołąb-Janowska M, Stępniewski J, Kotowski M, et al. Safety and Feasibility of Lin- Cells Administration to ALS Patients: A Novel View on Humoral Factors and miRNA Profiles. Int J Mol Sci. 2018;27(19):E1312. doi: 10.3390/ijms19051312.
    1. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–299. doi: 10.1080/146608200300079536.
    1. Lortie CL, Thibeault M, Guitton MJ, Tremblay P. Effects of age on the amplitude, frequency and perceived quality of voice. Age (Dordr) 2015;37:117. doi: 10.1007/s11357-015-9854-1.
    1. Franic DM, Bramle RE, Bothe AC. Psychometric evaluation of disease specific quality of life instruments in voice disorders. J Voice. 2005;19:300–301. doi: 10.1016/j.jvoice.2004.03.003.
    1. Atkinson-Clement C, Letanneux A, Baille G, Cuartero MC, Véron-Delor L, Robieux C, et al. Psychosocial impact of dysarthria: the patient-reported outcome as part of the clinical management. Neurodegener Dis. 2019;21:1–10.
    1. Biddle AK, Watson LR, Hooper CR, Lohr KN, Sutton SF. Criteria for determining disability in speech-language disorders. Evid Rep Technol Assess (Summ). 2002;(52):1–4.
    1. Behlau M, dos Santos LDMA, Oliveira G. Cross-cultural adaptation and validation of the voice handicap index into Brazilian Portuguese. J Voice. 2011;25:354–359. doi: 10.1016/j.jvoice.2009.09.007.
    1. Bonetti A, Bonetti L. Cross-cultural adaptation and validation of the voice handicap index into Croatian. J Voice. 2013;27:130–137. doi: 10.1016/j.jvoice.2012.07.006.
    1. Helidoni ME, Murry T, Moschandreas J, Lionis C, Printza A, Velegrakis GA. Cross-cultural adaptation and validation of the voice handicap index into Greek. J Voice. 2010;24:221–227. doi: 10.1016/j.jvoice.2008.06.005.
    1. Schindler A, Ottaviani F, Mozzanica F, Bachmann C, Favero E, Schettino I, et al. Cross-cultural adaptation and validation of the voice handicap index into Italian. J Voice. 2010;24:708–714. doi: 10.1016/j.jvoice.2009.05.006.
    1. Trinite B, Sokolovs J. Adaptation and validation of the voice handicap index in Latvian. J Voice. 2014;28:452–457. doi: 10.1016/j.jvoice.2014.01.008.
    1. Pruszewicz A, Obrębowski A, Wiskirska-Woźnica B, Wojnowski W. W sprawie kompleksowej oceny głosu – własna modyfikacja testu samooceny niesprawności głosu (Voice Handicap Idex) Otolaryngol Pol. 2004;58:547–549.
    1. Pawlukowska W, Szylińska A, Kotlęga D, Rotter I, Nowacki P. Differences between subjective and objective assessment of speech deficiency in Parkinson disease. J Voice. 2018;32(6):715–722. doi: 10.1016/j.jvoice.2017.08.018.
    1. Roth C, Glaze L, Goding G, David W. Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis. J Voice. 1996;10:362–367. doi: 10.1016/S0892-1997(96)80028-2.
    1. Rosenfield DB, Viswanath N, Herbrich KE, Nudelman HB. Evaluation of the speech motor control system in amyotrophic lateral sclerosis. J Voice. 1991;5:224–230. doi: 10.1016/S0892-1997(05)80190-0.
    1. Yorkston KM, Strand E, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention. Int J Lang Commun Disord. 2018;53:385–392. doi: 10.1111/1460-6984.12357.
    1. Yunusova Y, Weismer G, Westbury JR, Lindstrom M. Articulatory movements during vowels in speakers with dysarthria and normal controls. J Speech Lang Hear Res. 2008;51:596–611. doi: 10.1044/1092-4388(2008/043).
    1. Hanson E, Yorkston K, Britton D. Dysarthria in amyotrophic lateral sclerosis: a systematic review of characteristics, speech treatment, and AAC options. J Med Speech-Lang Pathol. 2011;19:12–30.
    1. Barkmeier J, Jordan LS, Robin DA, Schum RL. Inexperienced Listener Ratings of Dysarthric Speaker intelligibility and Physical Appearance. In: Moore CA, editor. Dysarthria and apraxia of speech: Perspectives on management. Baltimore: Paul H. Brookes Publishing Co; 1991. pp. 65–75.
    1. Green JR, Yunusova Y, Kuruvilla MS, Wang J, Pattee GL, Synhorst L, et al. Bulbar speech motor assessment in ALS: challenges and future directions. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:494–500. doi: 10.3109/21678421.2013.817585.
    1. DePaul R, Brooks BR. Multiple orofacial indices in amyotrophic lateral sclerosis. J Speech Hear Res. 1993;36:1158–1167. doi: 10.1044/jshr.3606.1158.
    1. McDonald ER, Wiedenfeld SA, Hillel A, Carpenter CL, Walter RA. Survival in amyotrophic lateral sclerosis: the role of psychological factors. Arch Neurol. 1994;51:17–23. doi: 10.1001/archneur.1994.00540130027010.
    1. Mora JS, Salas T, Fajardo ML, Iváñez L, Rodríguez- Santos F. Self-perceived emotional functioning of Spanish patients with amyotrophic lateral sclerosis: a longitudinal study. Front Psychol. 2013;3:609. doi: 10.3389/fpsyg.2012.00609.
    1. Pagnini F. Psychological well-being and quality of life in amyotrophic lateral sclerosis: a review. Int J Psychol. 2013;48:194–205. doi: 10.1080/00207594.2012.691977.
    1. Abdulla S, Vielhaber S, Kollewe K, Machts J, Heinze HJ, Dengler R, et al. The impact of physical impairment on emotional well-being in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:392–397. doi: 10.3109/21678421.2014.932380.
    1. Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A. Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology. 2005;25:114–119. doi: 10.1159/000086353.
    1. Yunusova Y, Green JR, Wang J, Pattee G, Zinman L. A protocol for comprehensive assessment of bulbar dysfunction in amyotrophic lateral sclerosis. J Vis Exp. 2011;21:2422. doi: 10.3791/2422.
    1. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010;75:1270–1276. doi: 10.1212/WNL.0b013e3181f61311.
    1. Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017;10:205–215. doi: 10.2147/JMDH.S134992.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться